Curis Lifesciences Ltd
Curis Lifesciences Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q3 FY26 call signalled
1 of 3 strong
The short version
Curis Lifesciences plans to focus on own brand marketing, especially in Nigeria, Kenya, and Ghana, aiming to increase revenue from this segment from about 1% currently to 5-7% by FY27 and beyond. EBITDA margin expected to increase by 1-2% points by FY27-FY28, potentially reaching around 22-23%.
From Curis Lifesciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Curis Lifesciences plans to focus on own brand marketing, especially in Nigeria, Kenya, and Ghana, aiming to increase revenue from this segment from about 1% currently to 5-7% by FY27 and beyond.
- The company expects registration of 10 products in Nigeria by FY27, and expanded own brand marketing to contribute significantly to growth post-registration, likely by FY28.
- Merchant export and contract manufacturing revenues will progressively be replaced by higher-margin own brand products over 3-5 years, targeting 80% capacity utilization with 80% revenue from own brand marketing.
- Expansion will be supported by strategic partnerships, such as with Eurosun Pharmaceuticals in Nigeria, leveraging their local market knowledge.
2 more points from Curis Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Curis Lifesciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No major capex is planned currently; the company already has all required manufacturing machines.
- Focus is on utilizing existing capacity with improved working capital from the IPO for scaling operations.
- Capacity utilization target: 80%+ over the next 2-3 years without significant new capex.
- The company is shifting from low-margin job work towards higher-margin own-brand exports, which requires regulatory registrations and market development rather than heavy capital investments.
- Strategic investments involve product registrations and expanding market presence, especially in African markets like Nigeria and Kenya, through partnerships rather than large capital outlays.
2 more points from Curis Lifesciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Curis Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Currently, orders from 3 products in Kenya and 9 products from Yemen are active, but expected revenue from these is not significant in the next financial year.
- Nigeria is identified as a very good market with high potential, but financial constraints delayed product registration and entry; Nigeria is now prioritized for registration and marketing.
- Expansion plans include entering own-brand marketing with registration in Nigeria followed by scaling up products in Kenya for increased revenue.
- New product registrations are ongoing with registration timelines staggered; some products registered by FY23 end but commercial scale-up and revenue gains will take 1-2 years.
- Merchant exporter-driven contract manufacturing continues with stable existing orders replacing low-margin jobs.
2 more points from Curis Lifesciences Ltd's call on order book
Create a free account to keep reading this call
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Curis Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Curis Lifesciences Ltd Q3 FY26 results?
Curis Lifesciences plans to focus on own brand marketing, especially in Nigeria, Kenya, and Ghana, aiming to increase revenue from this segment from about 1% currently to 5-7% by FY27 and beyond. EBITDA margin expected to increase by 1-2% points by FY27-FY28, potentially reaching around 22-23%.
What is Curis Lifesciences Ltd share price analysis?
Curis Lifesciences Ltd currently shows a below-average growth signal. The stock trades at a P/E of 12.8 with a market cap of ₹89 Cr. Investors should review the full earnings analysis for detailed insights.
Is Curis Lifesciences Ltd planning capital expenditure?
No major capex is planned currently; the company already has all required manufacturing machines.
Keep Curis Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.